Market News AIOpen the app

CADL stock news · Candel Therapeutics, Inc.

Stories about Candel Therapeutics, Inc. (CADL) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CADL

Follow Candel Therapeutics, Inc. (CADL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CADL
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:13 PM ET · Market

    Candel Therapeutics shared its third-quarter results and updates on its drug application and clinical trials.

    Neutral

    Candel reported $203.1 million in cash, expected to fund operations into Q2 2028, and plans a prostate cancer approval application in mid-2027. New study findings are encouraging, but assay work and pending FDA talks leave the overall outlook unchanged.

  2. Sep 10, 2026, 8:20 AM ET · Market

    Candel Therapeutics added Martine Zimmermann to its Board of Directors and shared details about her pay and experience.

    Good for CADL

    Candel added Martine Zimmermann to its board, strengthening regulatory expertise; I read this as positive for CADL because it boosts regulatory experience on the board.

  3. Sep 9, 2026, 4:52 PM ET · Market

    Candel Therapeutics, Inc. shares important updates with investors in a new SEC filing.

    Neutral

    Candel furnished an investor presentation on an 8-K under Regulation FD; this routine disclosure does not change how I read the company today.